Harvard Biosci SEC Filings

Harvard Bioscience entered into a retention letter with Interim Chief Financial Officer Mark Frost to support a planned refinancing of its term loan and senior revolving credit facility. The agreement makes Mr. Frost eligible for a $100,000 retention bonus if the refinancing is completed prior to March 15, 2026, replacing a previously offered $50,000 cash bonus. Eligibility requires Mr. Frost to remain employed through the refinancing date and, unless earlier terminated by the company without cause, through the retention date. If terminated without cause before the retention date, Mr. Frost would receive five months of base salary and the company-paid portion of COBRA premiums, subject to execution of a general release. The full Retention Letter Agreement is filed as Exhibit 10.1 and is incorporated by reference.

John D. Duke, Chief Executive Officer and Director of Harvard Bioscience (HBIO), received awards totaling 1,000,000 restricted stock units (RSUs) reported as insider transactions dated 08/08/2025. 500,000 RSUs are time-based and vest in three equal installments on August 8, 2026, 2027 and 2028. A separate 500,000 RSU award is performance-based, vesting upon achievement of relative total shareholder return versus the Russell 2000 from August 8, 2025 to the earlier of July 30, 2028 or a change of control; the reported target is 500,000 RSUs with a maximum payout of 150% (up to 750,000). The Form reports 1,000,000 shares beneficially owned following the reported transactions, with the awards recorded at a price of $0.00, indicating grants rather than purchases.

Harvard Bioscience reported weaker sales and a large non-cash charge that materially worsened results for the six months. Revenue declined to $20.45 million in the quarter (down ~11.5% year-over-year) and to $42.22 million for the six-month period (down ~11.3%). The company recorded a $47.951 million goodwill impairment that drove a six-month net loss of $52.622 million (loss per share $1.19). Operating cash flow improved, providing $5.741 million for the six months, and cash and cash equivalents rose to $7.442 million from $4.108 million.

The balance sheet shows $34.864 million of debt (term loan $22.7 million; revolver $12.65 million) and continued covenant pressure. Management obtained a covenant waiver in August 2025 conditioned on completing a refinancing by December 2025, creating substantial doubt about the company’s ability to continue as a going concern unless refinancing or other capital is secured. The filing also discloses previously reported material weaknesses in internal controls that remain under remediation.

Harvard Bioscience entered into a Sixth Amendment to its Credit Agreement that waived defaults tied to missed refinancing milestones and the company's failure to meet its consolidated net leverage and fixed charge coverage covenants as of the June 30, 2025 test date. Lenders agreed not to test the financial covenants for the quarter ended September 30, 2025 provided the company remains current on payments, maintains minimum liquidity of $3.0 million and delivers certain financial reports.

The amendment raises the interest margin to SOFR + 700 bps, adds mandatory prepayment on receipt of refinancing or sale proceeds, and requires the company to take steps to refinance or repay the Credit Agreement by December 5, 2025 or face an event of default. The company will pay a fee of $0.4 million (1.00% of outstanding debt), with 25% paid at signing and the remainder payable on refinancing, repayment or default. The company discloses substantial doubt about its ability to continue as a going concern absent additional capital or refinancing.

Harvard Bioscience, Inc. announced a press release with financial results for the three and six months ended June 30, 2025, and scheduled a conference call at 8:00 AM ET on August 11, 2025. The Current Report (Form 8-K) states the press release is furnished as Exhibit 99.1 and that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except by specific reference in a future filing.

The report lists Exhibit 99.1 (press release) and Exhibit 104 (cover page interactive data) and is signed by Mark Frost, Interim Chief Financial Officer. No financial figures or performance metrics are provided within this 8-K; readers must consult Exhibit 99.1 for substantive results.

Harvard Bioscience (HBIO) – Form 4 filing

Director Seth B. Benson reported the grant of 110,000 restricted stock units (RSUs) on 16-Jul-2025. The RSUs were awarded at a price of $0.00 and will fully vest on the earlier of the company’s next Annual Meeting after 16-Jul-2025 or on 16-Jul-2026.

Following the grant, Benson beneficially owns 110,000 common shares, held directly. No derivative securities, option exercises or share sales were disclosed. The transaction reflects routine director equity compensation and does not signal any change to Harvard Bioscience’s operating outlook or capital structure beyond a modest increase in outstanding shares.

Harvard Bioscience (HBIO) filed an amended Form 8-K to restate Item 3.01 and confirm that Nasdaq has formally determined the company is out of compliance with Listing Rule 5605(c)(2)(A), which requires at least three independent directors on the audit committee. The shortfall was triggered by director Alan Edrick’s resignation on 10 Jun 2025, leaving only two audit-committee members. Nasdaq’s notice was received on 26 Jun 2025.

HBIO states it will appoint a new, fully independent director “as expeditiously as practicable” and will rely on the cure period in Rule 5605(c)(4), giving the company until the earlier of its next annual shareholders’ meeting or 10 Jun 2026 to regain compliance. Until then, the company remains subject to potential delisting if it fails to add a qualified director within the allowed timeframe. No financial statements, earnings metrics or transactional details were included in this filing.